A Cost-Benefit Analysis of the COVID-19 Asymptomatic Mass Testing Strategy in the North Metropolitan Area of Barcelona
Francesc López Seguí(Universitat de Vic - Universitat Central de Catalunya), Jordi Ara del Rey, Anna Aran Solé, Oriol Estrada, Bonaventura Clotet(IrsiCaixa), Martí Català(Nuffield Orthopaedic Centre), Mar Isnard Blanchar, Nemesio Moreno Millán, Ignacio Blanco, Josep Maria Bonet, Núria Prat, Marc Vilar Capella, Josep Maria Argimón Pallàs(Ministry of Health), Guillem Hernández Guillamet(Universitat Pompeu Fabra)
International Journal of Environmental Research and Public Health
June 30, 2021
Cited by 30
Related Papers
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance
|Genetics in Medicine|2015|265